Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

PHASE4CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions
HIVContraception
Interventions
DRUG

Depot medroxyprogesterone acetate (DMPA)

DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.

DEVICE

Etonogestrel implant (Eng-Implant)

A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.

DEVICE

Levonorgestrel intrauterine device (Lng-IUD)

A standard Mirena IUD will be placed at study week 3 by a trained clinician.

DEVICE

ParaGard® T 380A Intrauterine Copper Contraceptive

A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.

Trial Locations (4)

30303

Grady Health System, Atlanta

30308

The Ponce de Leon Center of the Grady Health System, Atlanta

30322

Emory Clinic, Atlanta

Emory University Clinical Research Network, Atlanta

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Lisa Haddad

OTHER

NCT02357368 - Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk | Biotech Hunter | Biotech Hunter